Atlas Trials

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Clinical trial NCT06116578 · WITHDRAWN

Trial details

NCT number
NCT06116578
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2025-01-01
Primary completion
2027-07-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.